A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer.
We examined the immunologic effects of allogeneic hematopoietic stem cell transplantation (HSCT) in the treatment of pancreatic ductal adenocarcinoma, a deadly disease with a median survival of 24 months for resected tumors and a 5-year survival rate of 6%. After adjuvant chemotherapy, 2 patients with resected pancreatic ductal adenocarcinoma underwent HSCT with HLA-identical sibling donors. Comparable patients who underwent radical surgery, but did not have a donor, served as controls (n=6). Both patients developed humoral and cellular (ie, HLA-A*01:01-restricted) immune responses directed against 2 novel tumor-associated antigens (TAAs), INO80E and UCLH3 after HSCT. Both TAAs were highly expressed in the original tumor tissue suggesting that HSCT promoted a clinically relevant, long-lasting cellular immune response. In contrast to untreated controls, who succumbed to progressive disease, both patients are tumor-free 9 years after diagnosis. Radical surgery combined with HSCT may cure pancreatic adenocarcinoma and change the cellular immune repertoire capable of responding to clinically and biologically relevant TAAs.
*Division of Clinical Immunology and Transfusion Medicine ¶Center for Allogeneic Stem Cell Transplantation ∥Division of Therapeutic Immunology (TIM) Departments of §Laboratory Medicine, Division of Pathology ‡Surgical Gastroenterology #Radiology, Karolinska Institutet, Karolinska University Hospital Huddinge †Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH-Royal Institute of Technology, Stockholm, Sweden.
Brigitta
B
Omazic
Burcu
B
Ayoglu
Matthias
M
Löhr
Ralf
R
Segersvärd
Caroline
C
Verbeke
Isabelle
I
Magalhaes
Zuzana
Z
Potacova
Jonas
J
Mattsson
Alexei
A
Terman
Sam
S
Ghazi
Nils
N
Albiin
Nikolaos
N
Kartalis
Peter
P
Nilsson
Thomas
T
Poiret
Liu
L
Zhenjiang
Rainer
R
Heuchel
Jochen M
JM
Schwenk
Johan
J
Permert
Markus J
MJ
Maeurer
Olle
O
Ringden